The Board of the Swiss Group for Clinical Cancer Research (SAKK) has elected Vincent Gruntz as its new CEO. The 43-year-old economist, who has a wealth of experience in healthcare and the pharmaceutical industry, will succeed Dr. Hans Rudolf Keller, who is leaving SAKK.